RTW Participates in $56 Million Financing Round in Biomea Fusion
RTW Venture Fund Limited (the Company ), the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note the announcement by Biomea Fusion, Inc. ( Biomea ) on 06 January 2021 of its completion of a $56 million Series A financing round.
The Company, alongside other investment vehicles of RTW Investments, LP (the Investment Manager ), confirms that it participated in the financing round together with other investment firms.
Biomea is a US-based privately held precision oncology company dedicated to developing innovative medicines targeting specific cancer driving mutations. Biomea plans to use the proceeds from the financing round to advance the development of its portfolio of irreversible inhibitors, including a potentially first-in-class irreversible inhibitor of menin, a key newly recognized onco-target